Lb Pharmaceuticals Inc
LBRX Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$39.34
KIRA · Stoqly’s AI analyst, in plain words
- Lb Pharmaceuticals Inc lost $25.2M in fiscal 2025.
- Free cash flow was −$35.3M in fiscal 2025, — of revenue.
Market cap
$1.2B
P/E
1.7x
Revenue
—
Net income
−$25.2M
Free cash flow
−$35.3M
Operating margin
—
Lb Pharmaceuticals Inc in 30 seconds · fiscal 2025
Does it make a profit?
−$25.2M
No. It lost money last year.
How is the share priced?
1.7x
One share costs 1.7 times its yearly profit per share.
What Lb Pharmaceuticals Inc does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 26, 2026
- Legal name
- LB PHARMACEUTICALS INC
- CIK
- 0001691082
Lb Pharmaceuticals Inc · LBRX
Results and finances
The last 2 fiscal years. Amounts in USD.
| Fiscal year | FY24 | FY25 |
|---|---|---|
| Sales and profit | ||
| Net income | −$63.1M | −$25.2M |
| Diluted EPS | −$176.15 | −$3.13 |
| Cash | ||
| Cash from operations | −$53.1M | −$35.2M |
| Capital expenditure | $0.8M | $0.1M |
| Free cash flow | −$53.8M | −$35.3M |
| Share count change | — | 2,146.0% |
| Debt and strength | ||
| Cash and short-term investments | $28.0M | $295M |
| Shareholders' equity | −$94.6M | $301M |
| Current ratio | 3.6x | 41.4x |
| Returns and quality | ||
| Return on equity | — | −24.4% |
| Return on tangible equity | — | −0.0% |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Lb Pharmaceuticals Inc · LBRX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $39.34 a share, the company is worth $1.2B: 1.7 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001691082). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.